Tuesday, July 31, 2012

Celtrion Receives approval for Remicade Biosimilar in South Korea

Celtrion has received marketing approval for its biosimilar version of Remicade (infliximab) in South Korea. The biosimilar version has been approved for the same indications as Remicade which includes RA, ankylosing spondylitis, ulcerative colitis, psoriasis and Crohn's disease.  A launch in other Asian countries and South America is expected by end of this year.